Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine which of three different dose combinations
of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is
most effective and safe. Tipranavir is an investigational protease inhibitor which has been
demonstrated to have in vitro activity against HIV-1.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
HIV Protease Inhibitors Protease Inhibitors Ritonavir Tipranavir